New Trial Data, PTV News: May 05, 2010

Episode Loading...

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: New Trial Data, PTV News: May 05, 2010
Released on: May 05, 2010. © PharmaVentures Ltd
Visitors: You are watching a 1 minute preview.
Share/save this page:
Follow us:
  • Summary
  • Transcript
  • Participants
  • Company
Pharmasset announce promising results for experimental Hepatitis C therapy
Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.
Shreesh Saurya
Senior Advisor

Shreesh is a seasoned expert in corporate strategy and financial analysis, a trusted advisor to senior executives of leading pharmaceutical and biotechnology companies. With over ten years of experience in the Pharma/Biotech industry he has worked in multiple sectors of academia, pharmaceutical corporations and life sciences management consultancies. His experience spans several therapy areas and whole value-chain, from R&D to Marketing and Sales. His expertise lies in industry and company analysis, strategic planning, competitor analysis, valuations, simulations, innovation management and marketing strategies. Shreesh has a PhD from the University of Cambridge and an MBA from the University of Oxford, Said Business School. He is also a Level III candidate in the CFA program.
PharmaVentures Ltd
PharmaVentures is a company that has proven success in deals and alliances.

PharmaVentures offers:

• Over 18 years of healthcare industry experience

• Experience gained from working with in excess of 1000 clients in 38 countries, and conducting more than 450 assignments

• Over 40 specialist advisors, analysts and researchers

• Skills honed in many countries - 80% of its business comes from outside the UK
Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercialising novel drugs to treat viral infections. Its primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (“HCV”).